Vijaypd Ceutical Ltd
Incorporated in October 1971, Vijaypd Ceutical Limited distributes pharmaceutical products and consumer goods, offering a comprehensive range of services.[1]
- Market Cap ₹ 177 Cr.
- Current Price ₹ 90.7
- High / Low ₹ 114 / 35.0
- Stock P/E 34.9
- Book Value ₹ 26.9
- Dividend Yield 0.00 %
- ROCE 11.6 %
- ROE 12.0 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.4.02 Cr.
- Debtor days have increased from 85.8 to 115 days.
- Working capital days have increased from 21.1 days to 64.7 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Industrials Capital Goods Electrical Equipment Heavy Electrical Equipment
Part of Nifty SME Emerge
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 51.09 | 59.15 | 117.09 | 98.96 | |
| 49.77 | 54.27 | 108.51 | 94.25 | |
| Operating Profit | 1.32 | 4.88 | 8.58 | 4.71 |
| OPM % | 2.58% | 8.25% | 7.33% | 4.76% |
| 1.82 | 0.00 | 0.78 | 4.02 | |
| Interest | 2.36 | 1.76 | 2.15 | 1.59 |
| Depreciation | 0.43 | 0.35 | 0.69 | 0.62 |
| Profit before tax | 0.35 | 2.77 | 6.52 | 6.52 |
| Tax % | 48.57% | 40.43% | 26.53% | 22.39% |
| 0.18 | 1.65 | 4.80 | 5.06 | |
| EPS in Rs | 3.42 | 2.59 | ||
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 25% |
| TTM: | -15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 204% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 17% |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.00 | 1.00 | 14.03 | 19.53 |
| Reserves | 4.93 | 5.59 | 18.14 | 33.01 |
| 25.57 | 24.45 | 21.77 | 33.67 | |
| 2.37 | 2.23 | 3.21 | 11.15 | |
| Total Liabilities | 32.87 | 33.27 | 57.15 | 97.36 |
| 2.73 | 2.43 | 8.44 | 8.72 | |
| CWIP | 0.00 | 0.00 | 0.11 | 1.66 |
| Investments | 0.16 | 0.15 | 0.25 | 2.09 |
| 29.98 | 30.69 | 48.35 | 84.89 | |
| Total Assets | 32.87 | 33.27 | 57.15 | 97.36 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 0.30 | 2.93 | -7.89 | -7.32 | |
| -0.09 | 12.78 | -0.55 | -12.17 | |
| -0.18 | -1.86 | -2.38 | 25.37 | |
| Net Cash Flow | 0.03 | 13.84 | -10.82 | 5.88 |
| Free Cash Flow | 0.28 | 2.87 | -8.64 | -9.46 |
| CFO/OP | 38% | 60% | -80% | -128% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 62.44 | 68.56 | 74.19 | 114.52 |
| Inventory Days | 30.97 | 28.85 | 42.60 | 46.48 |
| Days Payable | 15.44 | 5.13 | 7.71 | 31.77 |
| Cash Conversion Cycle | 77.96 | 92.29 | 109.07 | 129.23 |
| Working Capital Days | -83.94 | -60.10 | 58.73 | 64.69 |
| ROCE % | 14.75% | 20.40% | 11.59% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Inventory Levels Days |
|
|||
| Net Fixed Asset Turnover Times |
||||
| Employee Count Number |
||||
| Number of Customers Number |
||||
| Number of SKUs Number |
||||
| Number of Suppliers Number |
||||
| Warehousing Area Sq. Ft. |
||||
Extracted by Screener AI
Documents
Announcements
-
Outcome of Board Meeting
30 May 2026 - Audited FY26 results approved; profit ₹500.10 lakh; control acquired in Zen Pharmaceuticals from 1 Dec 2025.
-
Disclosure under SEBI Takeover Regulations
5 May 2026 - Promoter confirms no share encumbrance during FY ended 31 March 2026.
-
Agreements
30 April 2026 - Vijaypd Ceutical signed MoU with Ann Finechem LLP for ₹30.2 crore bulk API purchases over one year.
-
Structural Digital Database
25 April 2026 - SDD compliance certificate for FY2025-26 filed; 5 required events captured, no noncompliance.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
13 April 2026 - Company states corporate governance provisions are not applicable for quarter ended 31 March 2026.
Business Profile[1]
The company is a distributor and supplier of pharmaceutical and consumer goods. The company acts as a representative, dealer, agent, stockist, supplier, trader, and packer for pharmaceutical and wellness products. It operates across Western Suburban Mumbai, South Mumbai, Ratnagiri, Aurangabad, and Akola, serving 2,109+ pharmacies, clinics, and nursing homes as of March 31, 2025.